ZURICH, May 29, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.

2+ days of education, relationship-building, and uninterrupted private meetings between decision-makers and vendors focused on all aspects of hotel operations in leading hotels across the U.S. and ...

VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors ZURICH, May 29, 2025 (GLOBE ...

VERAXA is leveraging its proprietary BiTAC platform to develop highly specific dual-target oncology therapies with less off-tumor toxicity and enhanced tumor specificity. The Company is currently ...